{"id":"ckd-498-dose-2","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":{"chemblId":"CHEMBL3697182","moleculeType":"Small molecule","molecularWeight":"401.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CKD-498 dose#2 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to be effective in treating type 2 diabetes.","oneSentence":"CKD-498 dose#2 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:58.292Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05677438","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-12-20","conditions":"Androgenetic Alopecia","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CKD-498 dose#2","genericName":"CKD-498 dose#2","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-498 dose#2 is being studied in a Phase 2 clinical trial for the treatment of Androgenetic Alopecia in female patients. The trial is evaluating the safety and efficacy of CKD-498 in a randomized, double-blind, multi-center, parallel-group design.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}